MBFT is a clinical-stage animal health company developing and commercializing innovative checkpoint inhibitor immunotherapeutic vaccines for treatment and prevention of cancer in companion animals and prevention of infectious diseases in companion animals and livestock. Check-point inhibitors are the ‘hottest’ field in immunotherapy today. This platform technology will generate multiple innovative vaccines for global markets worth >$5B.